HIV (AIDS)

4,177,242views

HIV (AIDS)

Foundations

Foundations

Introduction to the immune system
Innate immune system
Complement system
Contracting the immune response and peripheral tolerance
Cytokines
Monoclonal antibodies
Antibody classes
Bacterial structure and functions
B-cell development
B-cell activation, differentiation, and contraction
T-cell development
T-cell activation
B- and T-cell memory
MHC class I and MHC class II molecules
Thymus histology
Cell cycle
Mitosis and meiosis
DNA replication
DNA damage and repair
DNA mutations
Cell membrane
Free radicals and cellular injury
Hypoxia
Necrosis and apoptosis
Inflammation
Crohn disease
Gout
Gout and pseudogout: Pathology review
Inclusion body myopathy
Inflammatory bowel disease: Pathology review
Papulosquamous and inflammatory skin disorders: Pathology review
Myasthenia gravis
Systemic lupus erythematosus
Type I hypersensitivity
Type II hypersensitivity
Type III hypersensitivity
Type IV hypersensitivity
Serum sickness
Anaphylaxis
Graft-versus-host disease
Systemic lupus erythematosus (SLE): Pathology review
Pemphigus vulgaris
Stevens-Johnson syndrome
Rheumatic heart disease
Heart failure: Pathology review
Thrombosis syndromes (hypercoagulability): Pathology review
Body fluid compartments
Movement of water between body compartments
Hyponatremia
Pulmonary edema
Lymphedema
Coagulation (secondary hemostasis)
Platelet plug formation (primary hemostasis)
Erythropoietin
Hemophilia
Coagulation disorders: Pathology review
Platelet disorders: Pathology review
Blood components
Protein C deficiency
Protein S deficiency
Metaplasia and dysplasia
Multiple endocrine neoplasia: Pathology review
Oncogenes and tumor suppressor genes
Amyloidosis
Atrophy, aplasia, and hypoplasia
Environmental and chemical toxicities: Pathology review
Medication overdoses and toxicities: Pathology review
Multiple endocrine neoplasia
Substance misuse and addiction: Clinical
Toxidromes: Clinical
Deep vein thrombosis and pulmonary embolism: Pathology review
Heparin-induced thrombocytopenia
Myocardial infarction
Shock
Arterial disease
Atherosclerosis and arteriosclerosis: Pathology review
Carbohydrates and sugars
Childhood nutrition and obesity: Information for patients and families (The Primary School)
Fat-soluble vitamin deficiency and toxicity: Pathology review
Folate (Vitamin B9) deficiency
Iron deficiency anemia
Osteomalacia and rickets
Vitamin B12 deficiency
Water-soluble vitamin deficiency and toxicity: B1-B7: Pathology review
Wernicke-Korsakoff syndrome
Zinc deficiency and protein-energy malnutrition: Pathology review
Burns: Clinical
Burns
Hyperplasia and hypertrophy
Down syndrome (Trisomy 21)
Edwards syndrome (Trisomy 18)
Patau syndrome (Trisomy 13)
Klinefelter syndrome
Turner syndrome
Angelman syndrome
Prader-Willi syndrome
Fragile X syndrome
DiGeorge syndrome
Phenylketonuria (NORD)
Homocystinuria
Maple syrup urine disease
Disorders of fatty acid metabolism: Pathology review
Ornithine transcarbamylase deficiency
Post-transplant lymphoproliferative disorders (NORD)
Cytomegalovirus infection after transplant (NORD)
Epigenetics
Gene regulation
Independent assortment of genes and linkage
Inheritance patterns
Mendelian genetics and punnett squares
Evolution and natural selection
Antiphospholipid syndrome
Celiac disease
Graves disease
Multiple sclerosis
Diabetes mellitus
Chronic granulomatous disease
Immunodeficiencies: Clinical
Immunodeficiencies: Phagocyte and complement dysfunction: Pathology review
Immunodeficiencies: Combined T-cell and B-cell disorders: Pathology review
Immunodeficiencies: T-cell and B-cell disorders: Pathology review
Candida
Mycobacterium tuberculosis (Tuberculosis)
Tuberculosis: Pathology review
Pneumonia: Pathology review
Pneumonia
Salmonella (non-typhoidal)
Viral structure and functions
Hepatitis medications
Herpesvirus medications
Neuraminidase inhibitors
HIV (AIDS)
Nucleoside reverse transcriptase inhibitors (NRTIs)
Integrase and entry inhibitors
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
Protease inhibitors
Vaccinations: Clinical
The flu vaccine: Information for patients and families
Vaccinations

Transcript

Watch video only

Content Reviewers

HIV, or human immunodeficiency virus, is a virus that targets cells in the immune system.

Over time, the immune system begins to fail which is called immunodeficiency, and this increases the risk of infections and tumors that a healthy immune system would usually be able to fend off.

These complications are referred to as AIDS, or acquired immunodeficiency syndrome.

Now there are two distinct types of HIV—HIV-1 and HIV-2.

HIV-1 is the more commonly associated with AIDS in the US and worldwide, HIV-2 is more rare, and typically restricted to areas in western Africa and southern Asia.

HIV-2 is so uncommon that “HIV” almost always refers to HIV-1.

Alright HIV targets CD4+ cells, meaning cells that have this specific molecule called CD4 on their membrane. Macrophages, T-helper cells, and dendritic cells are all involved in the immune response and all have CD4 molecules; therefore they can be targeted by HIV.

The CD4 molecule helps these cells attach to and communicate with other immune cells, which is particularly important when the cells are launching attacks against foreign pathogens.

So this little molecule is pretty important for our immune system, but it’s also extremely important for HIV. HIV targets and attaches to the CD4 molecule via a protein called gp120 found on its envelope.

HIV then again uses gp120 to attach to another receptor, called a co-receptor.

HIV needs to bind to both the CD4 molecule and a coreceptor to get inside the cell.

The most common co-receptors that HIV uses are the CXCR4 co-receptor, which is found mainly on T-cells, or the CCR5 co-receptor which is found on T-cells, macrophages, monocytes, and dendritic cells.

These coreceptors are so important that some people with homogeneous genetic mutations in their CCR5 actually have resistance or immunity to HIV, since HIV can’t attach and get into the cell.

In fact, even heterozygous mutations which lead to fewer co-receptors on the cells, can make it harder for the virus to spread, and results in a slower disease progression.

For those without this mutation though, once HIV binds to CD4 and either CCR5 or CXCR4, it gains access to the cell.

HIV is a single-stranded, positive-sense, enveloped RNA retrovirus, meaning that it injects its single strand of RNA into the T-helper cell.

The “retro” part of retrovirus isn’t referring to its style, but refers to it needing to use an enzyme called reverse transcriptase to transcribe a complementary double-stranded piece of “proviral” DNA.

Proviral just means that it’s ready to be integrated into the host’s DNA, so it enters the T-helper cell’s nucleus and pops itself into the cell’s DNA, ready to be transcribed into new viruses, pretty sneaky, huh?

Well here’s the actual sneaky part—when the immune cells become activated, they start transcribing and translating proteins needed for the immune response.

Ironically, this means that whenever the immune cell is exposed to something that causes it to start up an immune response, like any infection, the immune cell ends up inadvertently transcribing and translating new HIV viruses, which bud off from the cell membrane to infect more cells. Very sneaky indeed!

One thing to know is that HIV is notorious for making errors when it replicates and that during an infection it can mutate to create slightly different strains of viruses.

These viruses are all still considered “HIV” but behave slightly differently from each other and target different cells in the host, in fact that host cell preference is called viral tropism.

So let’s start with HIV entering the body through sexual intercourse which is how it typically spreads from person to person.

At this early point, during what we call acute infection, the R5 strain of HIV, which bind to the CCR5 coreceptor will get into macrophages, dendritic cells, and T cells.

Usually dendritic cells hanging out in the epithelial or mucosal tissue where the virus entered the body, capture the virus and migrate to the lymph nodes, where a lot of immune cells live, and the R5 strain of HIV essentially has a field day, infecting T-helper cells, macrophages, and more dendritic cells, which leads to a big spike in HIV replication and the amount of virus found in the patient’s blood.

Patients typically experience flu-like or mononucleosis-like symptoms during the acute infection.

In response, the immune system mounts a counterattack, and starts to control the amount of viral replication, and the amount of virus in the blood declines to lower but still detectable levels by 12 weeks—at which point the patient enters the chronic or clinically-latent phase, which can last between 2 and 10 years.

If we also plot the amount of T cells alongside the amount of virus, we’ll see that they loosely mirror each other, which makes total sense, right?